Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

10365	Companies
215860	Keywords
145590	Articles
114302	Press releases

Home
Companies
Biophytis

BRIEF

published on 09/11/2025 at 07:05, 7 months 26 days ago

Biophytis Lance un Essai de Phase 3 sur la Sarcopénie avec BIO101

Biophytis Essai Clinique Sarcopénie BIO101 Europe Et Asie
BRIEF

published on 09/11/2025 at 07:05, 7 months 26 days ago

Biophytis Announces Phase 3 Sarcopenia Trial for BIO101 in Europe and Asia

Age-related Diseases BIO101 Sarcopenia Clinical Trial Biophytis Strategy Asia And Europe
REGULATED PRESS RELEASE

published on 09/11/2025 at 07:00, 7 months 26 days ago

Biophytis dévoile sa stratégie d’essai de phase 3 dans la sarcopénie avec BIO101 en Europe et en Asie
Biophytis annonce sa stratégie d'essai de phase 3 pour la sarcopénie avec BIO101 en Europe et en Asie, ciblant un marché médical important et non satisfait

Biophytis Europe Asie Sarcopénie Phase 3
REGULATED PRESS RELEASE

published on 09/11/2025 at 07:00, 7 months 26 days ago

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia
Biophytis announces Phase 3 Sarcopenia Trial Strategy with BIO101 targeting age-related sarcopenia in Europe and Asia, aiming to address a significant unmet medical need and commercial market

Biophytis Clinical Trial Sarcopenia Phase 3 BIO101
PRESS RELEASE

published on 09/11/2025 at 06:59, 7 months 26 days ago

Biophytis dévoile sa stratégie d’essai de phase 3 dans la sarcopénie avec BIO101 en Europe et en Asie
Biophytis présente sa stratégie d'essai de phase 3 pour la sarcopénie avec BIO101 en Europe et Asie, visant à devenir pionnier dans ce domaine thérapeutique en croissance rapide

Biophytis Essai Clinique Sarcopénie Phase 3 BIO101
BRIEF

published on 09/03/2025 at 07:05, 8 months 4 days ago

Biophytis obtient l'approbation de l'EMA pour une étude clinique phase 2 sur l'obésité

Biophytis Essai Clinique Phase 2 Obésité EMA
BRIEF

published on 09/03/2025 at 07:05, 8 months 4 days ago

Biophytis Advances Obesity Treatment with EMA Approval

Biophytis Obesity Treatment Clinical Trial BIO101 EMA Authorization
REGULATED PRESS RELEASE

published on 09/03/2025 at 07:00, 8 months 4 days ago

Biophytis obtient l'autorisation de l'EMA pour le lancement de son étude clinique de phase 2 dans l’obésité
Biophytis obtient l'autorisation de l'EMA pour lancer l'étude clinique de phase 2 sur l'obésité en Europe et prépare le recrutement des patients. La société se réjouit de cette avancée réglementaire cruciale

Biophytis Étude Clinique Obésité Autorisation EMA
REGULATED PRESS RELEASE

published on 09/03/2025 at 07:00, 8 months 4 days ago

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity
Biophytis obtains EMA authorization to launch Phase 2 clinical trial of BIO101 in obesity, marking a significant regulatory milestone in Europe

Biophytis Phase 2 Clinical Trial Obesity EMA Authorization Regulatory Milestone
BRIEF

published on 09/01/2025 at 07:05, 8 months 6 days ago

Biophytis lance une phase 2 pour traiter l'obésité avec BIO101

Biophytis Essai Clinique Phase 2 BIO101 Obésité

Accesswire

Published on 05/07/2026 at 15:15, 26 minutes ago

ACCESS Newswire Launches ACCESS Insights & Analytics, AI-Powered Press Release Scoring Platform
Published on 05/07/2026 at 14:35, 1 hour 6 minutes ago

Worksport (NASDAQ: WKSP) Announces Q1 2026 Earnings Call Date and Launch of Investor Townhall Series
Published on 05/07/2026 at 14:30, 1 hour 11 minutes ago

Rio Grande Resources Announces Results of First Annual General Meeting and Re-Appointments
Published on 05/07/2026 at 14:30, 1 hour 11 minutes ago

Loar Holdings Inc. Reports Q1 2026 Record Results and Upward Revision to 2026 Outlook
Published on 05/07/2026 at 14:00, 1 hour 41 minutes ago

Adcore to Publish First Quarter 2026 Results on May 14, 2026

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 15:28, 12 minutes ago

JOST’s Annual General Meeting approves dividend of EUR 1.50 per share and elects new Supervisory Board member
Published on 05/07/2026 at 15:10, 30 minutes ago

Elevated Materials Appoints Sunit Kapur as Chief Operating Officer
Published on 05/07/2026 at 15:05, 35 minutes ago

CELEBRATING FEET WITH A TOUCH OF COLOR: BIRKENSTOCK INTRODUCES NAIL POLISH COLLECTION
Published on 05/07/2026 at 14:56, 44 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 05/07/2026 at 14:54, 46 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc

Les Echos

Published on 05/07/2026 at 15:00, 41 minutes ago

Déclaration mensuelle du nombre total de droits de vote et du nombre d’actions composant le capital
Published on 05/07/2026 at 07:43, 7 hours 57 minutes ago

ENGIE - Q1 2026 financial information
Published on 05/07/2026 at 07:43, 7 hours 57 minutes ago

ENGIE - Information Financière 1er trimestre 2026
Published on 05/06/2026 at 18:00, 21 hours 40 minutes ago

Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 21 hours 40 minutes ago

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026

View all LES ECHOS COMFI WIRE